According to Future Market Insights, the Femtech Market would generate US$ 1.2 Billion in sales in 2023. The market as a whole is anticipated to reach US$ 5.0 Bn by 2033, growing at a CAGR of 15.2% from 2023 to 2033, driven by rising consumer awareness of women's health.

The global Femtech Market is expected to reach a valuation of US$3.8 Bn by the end of 2031, with sales growing at an astounding CAGR of 15% over the assessment period of 2021-2031. The market was valued at US$ 0.94 Bn in 2021. A rising demographic of working women and direct-to-consumer end users are expected to drive the market for the forecast period.

Rising cases of infectious diseases among women, growing awareness about general wellness, and the availability of multiple alternatives for educating and destigmatizing women’s health issues are responsible for the upsurge in the femtech market. The burden of infectious diseases like sexually transmitted infections (STIs) is a major driver of the femtech market. Menstrual care kits, pregnancy care, fertility issues, and maternity care, along with a growing awareness of women's reproductive health and sexual empowerment contribute to a surge in the demand for femtech services and solutions.

Request a Sample PDF: https://www.futuremarketinsights.com/reports/sample/rep-gb-11761

Technological advancements coupled with the emergence of software and applications designed solely for the purpose of assisting with reproductive health and fertility solutions are gaining traction over the past five years. With the rising adoption of these technologies, the femtech market is expected to witness growth over the forecast period. Digitalization of healthcare and better medical reimbursement policies are expected to propel market growth over the forecast period.

“Healthcare solutions, dealing with STIs, that are integrated with specialized modules of diagnosis and screening technologies will likely boost the market growth over the forecast period,” says an FMI analyst.  

Key Takeaways:

• STIs like HIV, chlamydia, syphilis, and others will likely propel the market over the forecast period.
• The U.K. femtech market is expected to grow at a CAGR of 14.1%.
• The U.S. market is expected to present lucrative market opportunities over the forecast period.
• China is projected to emerge as an attractive market in the East Asia region with over 52.5% of market share.
• India will account for 45.8% of market sales in the South Asia femtech market.
• Diagnostics services segment is expected to exhibit a CAGR of 13.3% over the forecast period.
• Menstrual health application segment is predicted to reach a market value of US$ 1358.0 Mn by 2031.

Competitive Landscape

Clue, Aparito Limited, Bloomlife, Bonzun Health Information AB, Elvie, Ava Science Inc., Grace Health, iBreve, LactApp, Natural Cycles Nordic AB, Hera Med Ltd., Niramai Health, NURX Inc., SteadySense GmbH, Pregnolia AG, Willow, WOOM, and B-wom among others are some of the manufacturers of femtech products nad solutions profiled in the full version of the report.

Key players in the global femtech market are employing several tactics like strategic partnerships and collaborations to provide unique and innovative solutions for women’s healthcare. Partnerships between major femtech organizations and pharmaceutical companies will give all the players involved a competitive advantage.

More Insights into the Femtech Market Report

In its latest report, FMI offers an unbiased analysis of the global femtech market, providing historical data from 2016 to 2020 and forecast statistics for the period 2021-to 2031. To understand the global market potential, growth, and coverage, the market is segmented based on service (diagnostics, monitoring, therapeutic), application (general health and wellness, maternity care, menstrual health, pelvic and uterine healthcare, cancer and chronic diseases), end user (direct-to-consumer, hospitals, surgical centers, fertility clinics, diagnostics centers) and region.

Femtech Market Segmentation Analysis

According to the recent report by FMI, the diagnostic services segment is set to account for a prolific CAGR of 13.3% over the assessment period. Growing cases of STIs and other women’s health issues have resulted in an elevated demand for enhanced diagnostic services. Rising awareness of health and hygiene among women coupled with the increasing availability of femtech solutions across digitalized platforms contribute to the segment’s growth.

Menstrual health segment, by application, is predicted to assume the lead in the market. Heightened menstrual health concerns along with growing awareness about reproductive health are expected to aid the segment’s growth in the femtech market. New adaptive menstrual health solutions also contribute to femtech market growth and expansion.

The direct-to-consumer segment is anticipated to account for 30.5% of the global femtech market share by the end of 2031. It is expected to grow at a CAGR of 12.9%. This is due to advancing digitalization and the introduction of multiple platforms that deal with women’s health. The user-friendly feature of the segment narrows the gap between diagnosis, prevention, and treatment. Thus contributing to market growth.

Femtech by Category

By Service

• Diagnostics
• Monitoring
• Therapeutic

By Application

• General Health and Wellness
• Maternity Care
• Menstrual Health
• Pelvic and Uterine Healthcare
• Cancer and Chronic Disease

By End User

• Direct-to-consumer
• Hospitals
• Surgical Centers
• Fertility Clinics
• Diagnostics Centers